Stock of the Day

March 25, 2022

Incyte (INCY)

$123.22
-$1.15 (-0.9%)
Market Cap: $25.21B

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Trend

Incyte Corporation (NASDAQ: INCY) shares are pulling back after a sharp rally driven by strong second-quarter results and improved 2026 guidance. The recent decline appears to reflect profit-taking and mixed analyst views, rather than a deterioration in the company’s operating outlook.

  • Incyte reported adjusted earnings of $3.09 per share and revenue of $1.67 billion, exceeding consensus estimates of $2.15 and $1.50 billion, respectively. Revenue increased 37.7% year over year. Incyte Stock Price Up on Better-Than-Expected Earnings
  • Management raised its 2026 outlook for net sales to $5.13 billion-$5.26 billion and lifted Opzelura guidance to $1.05 billion-$1.10 billion, helped by a favorable CMS settlement. The company now expects Opzelura to surpass $1 billion in annual sales. Incyte 2026 Sales and Opzelura Guidance
  • Several analysts raised their forecasts following the upbeat quarter. HC Wainwright increased its price target to $150 and retained a Buy rating, while BMO raised its target to $130. Analysts Raise Incyte Forecasts
  • Incyte says it is becoming less dependent on a single drug, pointing to broader pipeline progress, sales growth and business-development activity. Zacks also highlights the stock’s growth and momentum characteristics. Incyte Diversification Commentary
  • The stock’s retreat after its strongest session in a year suggests investors are locking in gains following the earnings-driven surge, despite European approval for Opzelura. Incyte Shares Retreat After Rally
  • Analyst sentiment remains mixed: UBS reiterated Hold with a $113 target, while BMO maintained Market Perform, indicating some analysts believe much of the improved outlook is already reflected in the shares. UBS Maintains Hold on Incyte
← Previous Stock of the DayNext Stock of the Day →

Recent News